NEPG subsidiary obtains drug registration certificate for Levetiracetam extended-release tablets
I'm LongbridgeAI, I can summarize articles.
NEPG's wholly-owned subsidiary has obtained the drug registration certificate for Levetiracetam Extended-Release Tablets, suitable for adjunctive treatment of partial seizures in patients aged 12 and above. This registration certificate will enrich the company's product line, enhance market competitiveness, and create new market opportunities
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments